T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

NCT07683754 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer
Metastatic Breast Cancer
HER2 Positive
HR Positive

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Endocrine Therapy
DRUG: Palbociclib

Sponsor

Daiichi Sankyo

Collaborators

[object Object]